Psychotropics India Ltd. . is presently undergoing a transformation & developing itself into a very fast growing pharmaceutical company. With a team of 800 plus highly motivated employees, it is moving in the direction of a strong medium size diversified organization. The present business model is very thoughtfully designed from its ethical division, followed by the newly launched generic division, contract manufacturing for leading Pharma houses of the country & into exports. The average growth rate for the last two years is more than twenty percent. Further the target for the next two years is planned at growth rate of twenty five percent each year, which the company is confident of achieving. The entry into Anti-biotics, Cosmetics and OTC products will further give a strong boost to its present sales. With more than 550 authorized stockists in its operational area and contact with more than thirty thousand qualified doctors through its sales force, on a regular basis. the company is growing from strength to strength.

The newly opened facility for the manufacturing of solid oral dosage form and dry syrups in beta-lactum category is fully operational and also has a low Rh area for the manufacture of clavulanate combinations. The overwhelming acceptance of the product portfolio in this category has further broadened the base of growth. The state of the art manufacturing facility for both small volume injectables & dry powder injectables at a project cost of USD 9 million in general & beta lactum category will roll out the products in December 2010. With global marketing ambitions, Psychotropics is emerging as a technology driven player offering high quality and cost effective healthcare.